Cara Therapeutics Company Profile (NASDAQ:CARA)

Analyst Ratings

Consensus Ratings for Cara Therapeutics (NASDAQ:CARA) (?)
Ratings Breakdown: 6 Buy Rating(s)
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $23.83 (292.00% upside)

Analysts' Ratings History for Cara Therapeutics (NASDAQ:CARA)
Show:
DateFirmActionRatingPrice TargetActions
5/6/2016Canaccord GenuityReiterated RatingBuy$30.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/6/2016Needham & Company LLCReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
4/23/2016Piper Jaffray Cos.Reiterated RatingOverweight$23.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
4/20/2016Cantor FitzgeraldReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
3/12/2016Janney Montgomery ScottReiterated RatingBuy$23.00 -> $18.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
2/29/2016LaidlawLower Price TargetBuy$30.00 -> $17.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
3/3/2015MLV & Co.Initiated CoverageBuy$26.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
12/9/2014Summer StreetInitiated CoverageBuy$20.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 7/26/2014 forward)

Earnings

Earnings History for Cara Therapeutics (NASDAQ:CARA)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallActions
8/8/2016        
5/5/2016Q116($0.40)($0.39)$0.03 million$0.01 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/10/2016Q4($0.33)($0.35)$0.53 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/9/2015Q315($0.27)($0.19)$1.86 million$2.40 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/10/2015Q215($0.24)($0.25)ViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/12/2015Q415($0.27)($0.21)$0.70 million$0.50 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/26/2015Q4($0.30)($0.18)$0.91 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/10/2014Q314($0.22)($0.29)$0.13 million$1.13 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/7/2014Q2($0.27)($0.16)$0.08 million$0.96 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/12/2014Q1($0.14)($0.22)$0.30 million$0.18 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/27/2014($0.18)($0.49)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Cara Therapeutics (NASDAQ:CARA)
No earnings estimates for this company have been tracked by MarketBeat.com

Dividends

Dividend History for Cara Therapeutics (NASDAQ:CARA)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Cara Therapeutics (NASDAQ:CARA)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionActions
4/20/2016Frederique Ph.D. MenzaghiVPSell6,000$9.00$54,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/17/2016Ventures Vi Lp RhoMajor ShareholderBuy400,000$4.87$1,948,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/3/2016Frederique Ph.D. MenzaghiVPSell6,000$9.04$54,240.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/26/2016Michael E LewisInsiderSell7,262$10.93$79,373.66View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/6/2016Derek T ChalmersCEOSell12,500$17.22$215,250.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/1/2015Frederique Ph.D. MenzaghiVPSell6,000$16.21$97,260.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/2/2015Frederique Ph.D. MenzaghiVPSell6,000$14.26$85,560.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/1/2015Frederique Ph.D. MenzaghiVPSell6,000$13.95$83,700.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/1/2015Frederique Ph.D. MenzaghiVPSell7,000$18.63$130,410.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/18/2015Josef SchoellCFOBuy3,000$22.10$66,300.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/1/2015Michael E LewisInsiderSell7,262$9.50$68,989.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/19/2015Dean SlagelDirectorSell188,811$10.02$1,891,886.22View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/1/2015Michael E LewisInsiderSell7,262$9.90$71,893.80View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/2/2015Michael E LewisInsiderSell7,262$10.11$73,418.82View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/2/2015Michael E LewisInsiderSell7,262$10.60$76,977.20View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/5/2014Ventures Vi Lp RhoMajor ShareholderBuy225,818$11.00$2,483,998.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Cara Therapeutics (NASDAQ:CARA)
DateHeadline
07/26/16 08:26 AMTwo Movers within Analysts Observation: Cara Therapeutics, Inc. (NASDAQ:CARA) , Globus Medical, Inc. (NYSE:GMED) - Street Updates
07/26/16 08:00 AMSix Major Biotech Acquisitions You Could See in 2016 (Part 3) -
07/25/16 09:09 PMMix Wondering Stocks- Valeant Pharmaceuticals International (NYSE:VRX), Cara Therapeutics (NASDAQ:CARA ... - Seneca Globe
07/25/16 03:37 PMCan Shares Of Cara Therapeutics, Inc. (NASDAQ:CARA) Hit $25? - Investor Newswire
07/25/16 03:37 PMCan Shares Of Cara Therapeutics, Inc. (NASDAQ:CARA) Hit $25? - Investor Newswire
07/25/16 03:37 PMBiotech Volatile Stocks: Lpath Inc. (NASDAQ:LPTN), Cara Therapeutics Inc. (NASDAQ:CARA), Galena Biopharma Inc ... - KC Register
07/25/16 03:37 PMBiotech Volatile Stocks: Lpath Inc. (NASDAQ:LPTN), Cara Therapeutics Inc. (NASDAQ:CARA), Galena Biopharma Inc ... - KC Register
07/25/16 03:37 PMAnalysts Suggestion Alert: Cara Therapeutics, Inc. (NASDAQ:CARA ... - Street Updates
07/25/16 03:37 PMCara Therapeutics Inc. (NASDAQ:CARA) Insiders Seem Vary About ... - Review Fortune
07/25/16 03:37 PMHC Stocks to Path: CIGNA Corporation (NYSE:CI) Cara ... - share market updates (press release)
07/25/16 07:51 AMBiggest Moving Stocks Pre Market – TCCO, CADC, TOPS, SPU, CARA, EVK, SMIT
07/24/16 07:44 AMPrice Target Estimates: Cara Therapeutics Inc. (NASDAQ:CARA) - News Oracle
07/23/16 07:22 AMCara Therapeutics Inc. (CARA) Jumps 21.8% on July 22 - Equities.com
07/23/16 07:22 AMCara Therapeutics Inc (CARA) Bull Gap Draws Options Traders - Schaeffers Research (blog)
07/22/16 03:07 PMCara Therapeutics Inc (CARA) Bull Gap Draws Options Traders
07/22/16 11:13 AMEarnings Focus and Crowd Sourced Sentiment Review for Cara Therapeutics, Inc. (NASDAQ:CARA) - TGP
07/21/16 07:22 AMStock Moving Lower for the Month; Investor Update on Cara Therapeutics Inc. (NASDAQ:CARA) - Engelwood Daily
07/20/16 10:22 PMCould Cara Therapeutics Inc Lose Strenght? The Stock Increases A Lot Today - Press Telegraph
07/20/16 11:03 AMPruritus Therapeutics Market Size and Key Trends in Terms of Volume and Value 2020
07/19/16 08:25 PMCara Therapeutics Incorporated (NASDAQ:CARA) Shorted Shares Increased By 39.33% - Consumer Eagle
07/19/16 03:06 PMCara Therapeutics, Inc. (NASDAQ:CARA): Sell-Side Ratings and Company Earnings Glance - Engelwood Daily
07/19/16 09:18 AMTrading Performance and Target Watch for Cara Therapeutics, Inc. (NASDAQ:CARA) - Press Telegraph
07/19/16 09:18 AMIs $25 Price Target Attainable For Cara Therapeutics, Inc. (NASDAQ:CARA)? - Investor Newswire
07/17/16 07:42 AMShares Moving Down on the Week: Cara Therapeutics Inc. (NASDAQ:CARA) - Engelwood Daily
07/17/16 07:42 AMHow Analysts Rated Cara Therapeutics Inc (NASDAQ:CARA) Last Week? - Consumer Eagle
07/15/16 06:37 PMShares Experiencing a Downtrend: Cara Therapeutics Inc. (NASDAQ:CARA) - TGP
07/15/16 06:37 PMCara Therapeutics' Data to be Presented at the British Association for Psychopharmacology 2016 Summer Meeting - GlobeNewswire (press release)
07/14/16 08:31 PMCara Therapeutics Inc's Stock Formed A Several Months Double Bottom - Press Telegraph
07/14/16 09:56 AMCara Therapeutics Incorporated (NASDAQ:CARA) Short Interest Decreased By 25.23% - Press Telegraph
07/13/16 03:48 PMCara Therapeutics' Data to be Presented at the British Association for Psychopharmacology 2016 Summer Meeting - [at noodls] - STAMFORD, Conn., July 13, 2016 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq:CARA), a biotechnology company focused on developing and commercializing new chemical entities designed to alleviate pain ...
07/13/16 03:30 PMCara Therapeutics’ Data to be Presented at the British Association for Psychopharmacology 2016 Summer Meeting - [GlobeNewswire] - STAMFORD, Conn., July 13, 2016-- Cara Therapeutics, Inc., a biotechnology company focused on developing and commercializing new chemical entities designed to alleviate pain and pruritus by selectively ...
07/13/16 03:04 PMLEASES: MJ Orbach and Kaufman Org. lease 21K s/f at 27W24, Communications firm takes 26K s/f in New Jersey
07/13/16 11:08 AMAnalyst Target and Average Rating Watch: Cara Therapeutics, Inc. (NASDAQ:CARA) - Press Telegraph
07/12/16 08:31 PMCara Therapeutics, Inc. (NASDAQ:CARA) Earnings Concentration and Analyst Target Watch - Engelwood Daily
07/12/16 08:31 PMCara Therapeutics Inc Realized Volatility Hits Extreme Level - CML News
07/12/16 03:08 PMUremic (Renal) Pruritus Global Clinical Trials Review, H1, 2016 - New Market Research Report
07/12/16 07:17 AMStrong Sell Calls For Cara Therapeutics, Inc. (NASDAQ:CARA) At 0 - Investor Newswire
07/12/16 07:17 AM1.02 is Cara Therapeutics Inc's (NASDAQ:CARA) Institutional Investor Sentiment - Consumer Eagle
07/10/16 02:57 PMCara Therapeutics Incorporated (NASDAQ:CARA) Shorts Decreased by 25.23% After Short Covering - Press Telegraph
07/09/16 07:40 AMPruritus Global Clinical Trials Review, H1, 2016 - New Market Report
07/08/16 03:05 PMCara Therapeutics (CARA) : Analyst Rating Update - Trade Calls
07/08/16 03:05 PMChoyce Peterson concludes lease for Cara Therapeutics' Stamford relocation - Westfair Online
07/08/16 03:05 PMCara Therapeutics Inc. Stock Momentum at Critical Inflection Point - CML News
07/08/16 11:03 AMChoyce Peterson concludes lease for Cara Therapeutics’ Stamford relocation
07/07/16 10:56 AMCara Therapeutics Inc (CARA) Updated Price Targets - FTSE News
07/06/16 03:10 PMIncreased Volatility Watch for: Cara Therapeutics Inc. (NASDAQ:CARA) - Engelwood Daily
07/06/16 03:10 PMBrokers Issue Average Price Target Of 23.33 On Cara Therapeutics Inc (CARA) - Fiscal Standard
07/06/16 03:10 PMCara Therapeutics Inc. (CARA) Jumps 6.24% on July 04 - Equities.com
07/05/16 02:04 PMFDA Approves Insys Therapeutics' 2nd Cannabis-Based Drug -
07/05/16 07:49 AMCara Therapeutics Incorporated (NASDAQ:CARA) Shorted Shares Decreased By 25.23% - Engelwood Daily

Social

About Cara Therapeutics

Cara Therapeutics logoCara Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing and commercializing chemical entities designed to alleviate pain and pruritus by focusing on kappa opioid receptors. The Company is engaged in developing product candidates that focus on the body's peripheral nervous system. Its product candidate pipeline includes I.V. CR845 for acute pain; I.V. CR845 for uremic pruritus; Oral CR845, and CR701. The Company's I.V. CR845 is an injectable version of peripheral kappa opioid receptor agonist, which is intended for the treatment of acute pain in an acute care setting. The Company is developing an oral version of CR845 for the treatment of moderate-to-severe acute and chronic pain. The Company's CR701 is a peripherally-restricted, mixed-CB1/CB2 receptor agonist that interacts with cannabinoid receptor subtypes, with no off-target activities. CR701 is in preclinical-stage of development.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: CARA
  • CUSIP:
Key Metrics:
  • Previous Close: $6.08
  • 50 Day Moving Average: $5.22
  • 200 Day Moving Average: $6.64
  • P/E Ratio: N/A
  • P/E Growth: 0.00
  • Market Cap: $165.87M
  • Beta: 2.84
  • Current Year EPS Consensus Estimate: $-1.68 EPS
  • Next Year EPS Consensus Estimate: $-1.57 EPS
Additional Links:
Cara Therapeutics (NASDAQ:CARA) Chart for Tuesday, July, 26, 2016